1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. Indiana >
  6. Assembly Bio Acquires Assembly Pharmaceuticals

M&A Deal Summary

Assembly Bio Acquires Assembly Pharmaceuticals

On May 19, 2014, Assembly Bio acquired healthcare services company Assembly Pharmaceuticals

Acquisition Highlights
  • This is Assembly Bio’s 1st transaction in the Healthcare Services sector.
  • This is Assembly Bio’s 1st transaction in the United States.
  • This is Assembly Bio’s 1st transaction in Indiana.

M&A Deal Summary
Date 2014-05-19
Target Assembly Pharmaceuticals
Sector Healthcare Services
Buyer(s) Assembly Bio
Deal Type Merger

Target

Assembly Pharmaceuticals

Bloomington, Indiana, United States
Assembly Pharmaceuticals is a virology-focused biopharmaceutical company with a discovery platform and programs based on proprietary Core Protein Allosteric Modulators (CpAMs) for the treatment of viral infections, starting with hepatitis B (HBV).

Search 214,600 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Assembly Bio

South San Francisco, California, United States
Category Company
Founded 2005
Sector Life Science
Employees65
Revenue 29M USD (2024)
DESCRIPTION

Assembly Bio is a biopharmaceutical company developing innovative treatments for hepatitis B virus infection (HBV) and C. difficile-associated diarrhea (CDAD). Assembly Bio was founded in 2005 and is based in South San Francisco, California.

DEAL STATS #
Overall 1 of 1
Sector: Healthcare Services M&A 1 of 1
Type: Merger M&A Deals 1 of 1
State: Indiana M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2014 M&A 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-25 Assembly Biosciences - Clinical-Stage M201 Program

San Francisco, California, United States

Assembly Biosciences' Clinical-Stage M201 Program is designed for patients with mild to moderate ulcerative colitis. M201 is comprised of a rationally designed consortium of commensal bacteria that were selected based on their ability to modulate ulcerative colitis-relevant cellular mechanisms in human cell-based assays and animal models.

Sell -
Mergr

Solution for

Product

Company

Legal